ChiCTR1800017056: Phase I Clinical Trial of CX13-608 in the Treatment of Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 56 | | iv infusion CX13-608 | Renji Hospital Affiliated to Medical School, Shanghai Jiaotong University; Ning Bo SanJian BIoPharmaceuticals, Inc, Company funding & Government support | Relapsed or Refractory Multiple Myeloma | | | | |